Coupling of Neural Activity and Retinal Blood Flow in Diabetes
The prevalence of diabetes is increasing and the management of the disease is nowadays considered a major challenge. Affected patients have increased mortality and morbidity as well as a significant drop in the quality of life. The complications of diabetes can be classified as microvascular (e.g. nephropathy, neuropathy or retinopathy) or macrovascular (e.g. cardiovascular or cerebrovascular).
Several large-scale epidemiologic studies indicating that wider retinal venous caliber is strongly associated with the fasting glucose level as well as with diabetes. Another retinal vascular abnormality that is associated with diabetes is an abnormal retinal vascular response to flicker stimulation. Retinal vessel dilatation in response to stimulation with diffuse flicker light occurs due to a phenomenon called neurovascular coupling. This means that increased activity of neurons is associated with an increased retinal metabolism. This leads to a release of endogenous vasodilator substances and increased blood flow. However, previous studies were limited by the fact that retinal vessel diameters and blood flow were not measured simultaneously.
The present study aims to investigate whether the response of retinal vessel diameters and blood flow velocities to flicker stimulation is altered in patients with diabetes. Both parameters will be measured in real time using Fourier Domain Doppler OCT.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Vienna, L'Autriche, 1090
- Department of Clinical Pharmacology
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Men and women aged over 18 years, nonsmokers
- Normal findings in the medical history (except diabetes) and physical examination unless the investigator considers an abnormality to be clinically irrelevant
- normal laboratory findings (except diabetes associated parameters) unless the investigator considers the abnormality to be clinically irrelevant
- normal ophthalmic findings (except mild diabetic retinopathy), Ametropia less than 6 diopters
- inclusion criterion of patients is type I diabetes with non or mild non-proliferative retinopathy
Exclusion criteria
Any of the following will exclude a healthy subject from the study:
- Regular use of vasoactive drugs
- Abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study
- Symptoms of a clinically relevant illness in the 3 weeks before the first study day
- Blood donation during the previous 3 weeks
- History or presence of any ocular pathology
- History or family history of epilepsy
- Systemic hypertension defined as systolic blood pressure >150mmHg, diastolic blood pressure >90mmHg
- Pregnancy
Any of the following will exclude a subject with diabetes from the study:
- Presence of non-insulin dependent diabetes, maturity onset diabetes of the young (MODY diabetes)
- History or presence of any other diabetes induced vascular pathologies or any other ocular condition other then diabetic retinopathy
- Best corrected visual acuity <0.8
- Previous laser photocoagulation treatment
- Systemic hypertension defined as systolic blood pressure >150mmHg, diastolic blood pressure >90mmHg
- History or family history of epilepsy
- Abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study
- Symptoms of a clinically relevant illness in the 3 weeks before the first study day
- Blood donation during the previous 3 weeks
- Pregnancy
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Diabetic retinopathy
Patients with early insulin dependent diabetes and no or mild non-proliferative retinopathy
|
|
healthy
healthy control subjects
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Retinal vessel diameters
Délai: 18 months
|
18 months
|
|
Retinal blood flow velocities
Délai: 18 months
|
18 months
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- OPHT-070111
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .